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Abstract
Background: Adherence to treatment and sputum smear conversion after 2 months of treatment are thought to be
important for successful outcome of tuberculosis (TB) treatment.
Methods: Retrospective cohort study of new adult TB patients diagnosed in the first quarter of 2007 at 48 clinics in Rwanda.
Data were abstracted from TB registers and individual treatment charts. Logistic regression analysis was done to examine
associations between baseline demographic and clinical factors and three outcomes adherence, sputum smear conversion
at two months, and death.
Results: Out of 725 eligible patients the treatment chart was retrieved for 581 (80%). Fifty-six (10%) of these patients took
,90% of doses (defined as poor adherence). Baseline demographic characteristics were not associated with adherence to
TB treatment, but adherence was lower among HIV patients not taking antiretroviral therapy (ART); p = 0.03). Sputum smear
results around 2 months after start of treatment were available for 220 of 311 initially sputum-smear-positive pulmonary TB
(PTB+) patients (71%); 175 (80%) had achieved sputum smear conversion. In multivariable analysis, baseline sputum smear
grade (odds ratio [OR] = 2.7, 95% Confidence interval [CI] 1.1–6.6 comparing smear 3+ against 1+) and HIV infection (OR 3.0,
95%CI 1.3–6.7) were independent predictors for non-conversion at 2 months. Sixty-nine of 574 patients (12%) with known
TB treatment outcomes had died. Besides other known determinants, poor adherence had an independent, strong effect on
mortality (OR 3.4, 95%CI 1.4–7.8).
Conclusion: HIV infection is an important independent predictor of failure of sputum smear conversion at 2 months among
PTB+ patients. Poor adherence to TB treatment is an important independent determinant of mortality.
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Introduction
Tuberculosis (TB) is a main cause of morbidity and mortality,
especially in resource-poor countries. According to the 2011
World Health Organization (WHO) Global TB Control report,
8.8 million new cases and 1.5 million deaths from TB occurred in
2010 [1]. Success of TB control rests on detection of new cases of
TB (for which the WHO has set a target of 70%) and on successful
treatment of those diagnosed (WHO target: 85%) [2]. Crucial to
achieving a successful treatment outcome is adherence to
treatment [3]. TB treatment usually lasts 6 or 8 months and low
adherence to treatment, including defaulting from treatment, is
one of the major challenges for control programs [4–6]. Among
sputum smear-positive pulmonary TB (PTB+) patients, smear
conversion after two months of intensive phase treatment is an
important predictor for bacteriological cure [7,8]. Poor adherence
to treatment may prolong infectiousness and increases the risk of
drug resistance, relapse, and death, as well as onward transmission
[3,9].
Rwanda is a densely populated country with an estimated
annual TB incidence rate of 376 per 100,000 population [10]. The
case detection rate is estimated to be only 19% [10]. In 2010 the
number of newly notified TB patients was 6,434 [1]. Out of the
4165 new PTB+ patients 85% had a favorable outcome [1]. The
HIV prevalence in the general population aged 15–49 years in
Rwanda is 3.0% [11], and it is estimated that one third of TB cases
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are HIV infected [12]. Little is known about mortality of patients
on TB treatment in Rwanda, and to what extent this is affected by
TB treatment adherence.
In this retrospective cohort study, we examined the determi-
nants of the following three outcomes: adherence to TB treatment,
sputum smear conversion at two months, and TB mortality. We
also examined the independent effect of adherence on mortality.
Methods
Diagnosis of TB
The diagnosis of pulmonary TB (PTB) in Rwanda is based on
sputum smear microscopy. Any person who is coughing for more
than 2 weeks should be considered a TB suspect and be invited for
Table 1. Baseline characteristics and follow-up data of 581
patients with tuberculosis, Rwanda, 2007.
N (%) or
median (IQR)



















PTB scanty or 1+ 109 (18.8)
PTB 2+ 109 (18.8)
PTB 3+ 93 (16.0)
PTB smear neg 64 (11.0)
PTB ‘‘microscopy not-done’’ 34 (5.9)












3. Treatment centre factors

















Took $90% of doses 480 (82.6%)
Took ,90% of doses 56 (9.6%)
No data 45 (7.8%)
Repeat C2 sputum smear status**
Negative sputum smear 226 (72.7%)
Positive sputum smear 52 (16.7%)
No sputum smear result 33 (10.6%)
Antiretroviral treatment
Not HIV infected 327 (56.3%)
HIV infected, on ART at time of start TB R/ 73 (12.6%)
HIV infected, started ART within 3 mo of start TB R/ 37 (6.4%)
HIV infected, not on ART or started .3 mo
after start of TB R/
132 (22.7%)
HIV status unknown, no ART 12 (2.1%)
Use of co-trimoxazole prophylaxis
Not HIV infected 327 (56.3%)
HIV infected, on co-trimoxazole at time of start TB R/ 107 (18.4%)
HIV infected, started co-trimoxazole within
3 mo of start TB R/
48 (8.3%)
HIV infected, not on co-trimoxazole or
started .3 mo after start of TB R/
87 (15.0%)
HIV status unknown, no co-trimoxazole 12 (2.1%)
Outcome
Cured 236 (40.6%)
Treatment completed 221 (38.0%)
Treatment failure 15 (2.6%)
Died 69 (11.9%)
Defaulted 13 (2.2%)
Transfer out 20 (3.4%)
Outcome not recorded 7 (1.2%)
Abbreviations: ART antiretroviral treatment; TB Tuberculosis; PTB pulmonary TB;
IQR inter-quartile range; HIV Human Immunodeficiency Virus; kg kilogram.
*Farming, housewives, unemployed, laborer, vendor;
**smear status 2 months after start of TB treatment (for details see text);
percentages based on those with smear positive PTB at baseline.
doi:10.1371/journal.pone.0073501.t001
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Table 2. Association of demographic and clinical characteristics with poor adherence in 536 newly identified TB patients, Rwanda,
2007.
Univariate analysis Multivariable analysis
Baseline characteristics N
n (%) with
poor adherence OR 95% CI P OR 95% CI P
Sex
Male 337 39 (11.6) 1 0.26 1 0.24
Female 199 17 (8.5) 0.71 0.39–1.30 0.69 0.37–1.29
Age (years)
15–24 129 14 (10.9) 1 0.99 1 0.74
25–34 187 19 (10.2) 0.93 0.45–1.93 0.74 0.34–1.59
35–44 119 12 (10.1) 0.92 0.41–2.08 0.60 0.24–1.49
$45 101 11 (10.9) 1.00 0.43–2.32 0.75 0.31–1.85
Occupation
Low-income group* 176 21 (11.9) 1 0.56
Students 41 2 (4.9) 0.38 0.09–1.68
Prisoners 21 0 (0.0) –
Employed 99 11 (11.1) 0.92 0.43–2.00
Not recorded 199 22 (11.1) 0.92 0.49–1.73
Type of TB
PTB scanty or 1+ 104 5 (4.8) 1 0.16
PTB 2+ 102 15 (14.7) 3.41 1.19–9.78
PTB 3+ 80 8 (10.0) 2.20 0.69–7.00
PTB smear neg 60 8 (13.3) 3.05 0.95–9.78
PTB ‘‘microscopy not-done’’ 30 5 (16.7) 3.96 1.06–14.75
Extra-pulmonary TB 152 14 (9.2) 2.01 0.70–5.76
Not recorded 8 1 (12.5)
HIV status
Negative 301 25 (8.3) 1 0.06
Positive 225 30 (13.3) 1.70 0.97–2.98
Not tested 10 1 (10.0)
Weight (kgs)
#48 188 20 (10.6) 1 0.77
49–55 170 18 (10.6) 0.99 0.51–1.95
$56 163 14 (8.6) 0.79 0.39–1.62
Not recorded 15 4 (26.7)
Location of health facility
Rural 63 6 (9.5) 1 0.80
Urban 473 50 (10.6) 1.12 0.46–2.74
District
Burera 13 1 (7.7) 1 0.75
Gakenke 21 1 (4.8) 0.60 0.03–10.51
Gasabo 119 14 (11.8) 1.60 0.19–13.26
Gicumbi 26 5 (19.2) 2.86 0.30–27.41
Kicukiro 999 12 (12.1) 1.66 0.20–13.89
Musanze 54 4 (7.4) 0.96 0.10–9.39
Ngororero 17 2 (11.8) 1.60 0.13–19.84
Nyarugenge 187 17 (9.1) 1.20 0.15–9.80
Antiretroviral therapy1
Not HIV infected 301 25 (8.3) 1 0.06 1 0.035
HIV infected, on ART 70 6 (8.6) 1.04 0.41–2.63 1.25 0.47–3.21
HIV infected, not on ART 155 24 (15.5) 2.02 1.11–3.68 2.36 1.22–4.55
TB Treatment Adherence in Rwanda
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sputum smear examinations. During the time of this study, the
Kinyoun staining technique was used [13]; in 2009, Ziehl-Neelsen
(ZN) staining was adopted [14]. At the time of study, a diagnosis of
PTB+ was made when at least 1 acid-fast bacillus (AFB) was
observed in 100 fields, in at least 2 out of 3 smears, according to
WHO guidelines (in Rwanda this criterion was later changed to a
single positive smear qualifying as PTB+ in accordance with
revised WHO guidelines [14]. The smear is graded according to
the number of AFBs found: scanty, 1+, 2+, or 3+ [13]. If all three
sputum smears are negative, but there is strong supportive
evidence for TB, a diagnosis of smear-negative PTB can be made.
In Rwanda it is a policy to test TB patients for HIV. Those found
to be HIV infected are referred for CD4 count testing.
Treatment of TB
The treatment regimen for new cases of TB in Rwanda consists
of a two month intensive phase with a daily dose of fixed-dose
combination tablets containing rifampicin (R), isoniazid (H),
pyrazinamide (Z) and ethambutol (E), followed by a four months
continuation phase of daily RH. To monitor treatment response of
smear-positive cases, sputum smear microscopy is done after the
second (C2), fourth and sixth month of treatment. PTB+ cases are
expected to convert to negative sputum smear status after the two
months of intensive treatment. Patients whose sputum smear has
not converted after two months of treatment are prescribed an
additional month of intensive phase treatment. The National
Tuberculosis Control Program in Rwanda (PNILT) follows the
WHO standard definitions of the six treatment outcomes (cure,
treatment completion, death, treatment failure, default, trans-
ferred-out) [8].
Study Design
We conducted a retrospective cohort study of TB patients in 3
of the 5 provinces of Rwanda. Kigali Province, which is
predominantly urban, and the Western and Northern Provinces,
which are mostly rural. From Kigali and the Northern provinces
all districts were included while one district (Ngororero) from the
Western province was included. Provinces and districts were
purposefully chosen to include both rural and urban areas, and
both central and peripheral areas. Patients with all forms of new
TB (PTB+, smear-negative PTB, PTB of unknown smear status,
and extrapulmonary TB [EPTB]), registered in all TB diagnostic
facilities (n = 48) from the selected districts in the first quarter of
2007 were included in the study. Patients less than 15 years of age
and those classified as previously treated cases were excluded.
Data of all eligible patients were abstracted in November and
December 2007 from the TB registers at the health facilities by
trained data collectors, using a standardised form. These data were
used to retrieve TB treatment charts for individual patients in the
period February to August 2008. Treatment charts are used by
treating physicians, nurses or other medical personnel to indicate
details of the individual patient’s condition, treatment prescribed
and treatment taken, and treatment outcomes. The patient
treatment charts were abstracted to obtain demographic informa-
tion, details of TB diagnosis (including sputum smear results), HIV
test results and treatment, information on number of daily doses
taken, and treatment outcome. CD4 count data were very
incomplete and not done at standardised moments, and were
not included in the analyses.
Study Outcomes
The outcomes of interest in this study included: (1) adherence to
TB treatment; (2) sputum smear conversion after two months of
TB treatment (among PTB+ patients only); (3) mortality during
TB treatment.
Adherence to TB treatment was defined as good if 90% or more
of expected TB medication doses were taken, and defined as poor
if less than 90% of the doses were taken [15]. The expected
number of doses was calculated as the number of days between the
start of treatment and the date of treatment completion, or date of
death, default, or treatment failure, as appropriate. Thus, even
patients who died within six months of start of TB treatment could
achieve 100% adherence as only the period that they were alive
was included in the denominator. Also, patients who took 168
doses (i.e. the number of doses to complete treatment: 6 months
times 28 days) of treatment could be classified as non-adherent, if
they needed more than 187 days (168/187 = 90%) to complete
their treatment (due to interruptions). Patients who were
transferred out were excluded from this analysis, as data on doses
taken were very incomplete in this group.
Sputum smear conversion after two months was defined as a
negative smear result from a sputum sample that was obtained at
least 7 weeks and not more than 9 weeks after the start of the TB
treatment in patients diagnosed with PTB+.
Ethics
This was a retrospective study making use of data already
collected; all data used in this report were routine clinical data
Table 2. Cont.
Univariate analysis Multivariable analysis
Baseline characteristics N
n (%) with
poor adherence OR 95% CI P OR 95% CI P
Unknown HIV status 10 1 (10.0)
Co–trimoxazole prophylaxis1
Not HIV infected 301 25 (8.3) 1 0.17
HIV+, on co-trimoxazole 103 13 (12.6) 1.59 0.78–3.25
HIV+, not on co-trimoxazole 122 17 (13.9) 1.79 0.93–3.44
Unknown HIV status 10 1 (10.0)
*Farming, housewives, unemployed, laborer, vendor.
ART antiretroviral therapy, OR Odds Ratio, aOR ajusted Odds Ratio, CI Confidence Interval, PTB Pulmonary TB.
1On ART/co-trimoxazole: on this treatment before or at the time of start of TB treatment; not on ART/co-trimoxazole: started with this treatment after starting TB
treatment or not at all.
doi:10.1371/journal.pone.0073501.t002
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Table 3. Association of sputum smear conversion after 2 months of intensive treatment phase with baseline characteristics in 220




after 2 months Univariate analysis Multivariable analysis
{
OR 95% CI P OR 95% CI P
Sex
Male 156 35 (22.4%) 1 0.25 1 0.24
Female 64 10 (15.6%) 0.64 0.30–1.39 0.61 0.27–1.39
Age (years)
15–24 66 12 (18.2%) 1 0.45 1 0.19
25–34 81 14 (17.3%) 0.94 0.40–2.20 0.53 0.21–1.36
35–44 40 9 (22.5%) 1.31 0.49–3.45 0.68 0.22–2.10
$45 33 10 (30.3%) 1.96 0.74–5.17 1.39 0.48–4.01
Occupation
Low-income group* 88 26 (29.6%) 1 0.12
Students 21 3 (14.3%) 0.40 0.11–1.47
Prisoner 10 0 (0%) –
Employed 43 7 (16.3%) 0.46 0.18–1.18
Not recorded 58 9 (15.5%) 0.44 0.19–1.02
Smear grade category
PTB scanty or 1+ 73 10 (13.7%) 1 0.12 1 0.087
PTB 2+ 82 17 (20.7%) 1.65 0.70–3.87 1.54 0.63–3.77
PTB 3+ 65 18 (27.7%) 2.41 1.02–5.70 2.69 1.09–6.63
HIV status
Negative 159 25 (15.7%) 1 0.009 1 0.008
Positive 59 19 (32.2%) 2.55 1.27–5.09 2.99 1.33–6.71
Not tested 2 1 (50.0%)
Weight (kgs)
#48 79 19 (24.1%) 1 0.63
49–55 73 13 (17.8%) 0.68 0.31–1.51
$56 64 13 (20.3%) 0.80 0.36–1.79
Not recorded 4 0 (0%)
Location of health facility
Rural 45 11 (24.4%) 1 0.46
Urban 175 34 (19.4%) 0.75 0.34–1.62
District
Burera 7 2 (28.6%) 1 0.059
Gakenke 20 8 (40.0%) 1.67 0.26–10.8
Gasabo 40 8 (20.0%) 0.63 0.10–3.83
Gicumbi 16 1 (6.3%) 0.17 0.01–2.26
Kicukiro 42 5 (11.9%) 0.34 0.05–2.22
Musanze 14 2 (14.3%) 0.42 0.05–3.83
Ngororero 10 5 (50.0%) 2.50 0.32–19.5
Nyarugenge 71 14 (19.7%) 0.61 0.11–3.50
Antiretroviral treatment#
Not HIV infected 159 25 (15.7) 1 0.017
HIV+, not on ART 46 13 (28.3) 2.11 0.98–4.56
HIV+, on ART 13 6 (46.2) 4.59 1.42–14.8
Unknown HIV status 2
Co-trimoxazole prophylaxis#
Not HIV infected 159 25 (15.7) 1 0.026
TB Treatment Adherence in Rwanda
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collected in the process of diagnosis and treatment. The processing
and analysis of data was done after anonymization. Therefore no
informed consent was requested from patients. This approach was
reviewed and approved by the Rwanda National Ethics Commit-
tee and the Research Ethics Committee of the Academic Medical
Center (AMC), Amsterdam, the Netherlands. The funders of the
study had no role in the analysis or the decision to publish the
data.
Statistical Analysis
Data were double entered into a SQL server platform database
(Microsoft, USA) and analysed using Stata version 11 (Stata
Corporation, College Station, TX, USA). We examined the
association of various baseline characteristics on the three study
outcomes (i.e. adherence; sputum smear conversion at C2; death).
Differences between categories were analysed using the chi-
squared test or Fisher’s exact test, as appropriate. The distributions
of continuous variables (these were not normally distributed) were
compared between groups using the rank sum test.
Logistic regression was used to identify factors that were
independently associated with the study outcome measures. As we
examined relatively few baseline characteristics (sex, age group,
occupation, type of TB, HIV status, use of antiretroviral treatment
(ART), use of co-trimoxazole prophylaxis, weight, and location of
facility) these were all included in a starting model. In the analyses
use of ART or co-trimoxazole prophylaxis was defined as being on
ART or co-trimoxazole prophylaxis before starting TB treatment.
Using the likelihood ratio test, we eliminated variables one by one
from the model (if p.0.05) until a parsimonious model was
obtained. Sex and age group were forced into the models, because
they were a priori thought to have a major impact on outcomes. P
values below 0.05 were considered significant.
Results
In the first quarter of 2007 a total of 725 new TB patients
fulfilling the eligibility criteria were identified from the TB registers
in the 48 facilities. From 581 of these 725 the treatment charts
were retrieved (80%). The 144 patients of whom the treatment
card could not be retrieved were not different in terms of age and
failure to convert at C2, but tended to be more often female (47%
vs. 38%; p = 0.052); they more often had EPTB (40% vs. 28%;
p = 0.027), and their treatment outcome was significantly more
often death (21% vs. 12%; p = 0.003) or transfer out (51% vs. 3%;
p,0.001). Our subsequent analyses are based on the 581 patients
of whom the treatment card could be retrieved and are thus based
on a population with, on average, better TB treatment outcomes.
The number of new TB patients per health facility varied
between 0 and 55 (median 4.5); from seven clinics no patients were
included in the study. In Table 1 the baseline characteristics of the
581 patients are summarised. Sixty-two percent were male, and
the median age was 31 years (range 15–86 years). Forty-two
percent of patients were HIV infected at the time of TB diagnosis.
Among the PTB+ patients 29% (90/311) were HIV infected, and
among all other TB patients 55% (145/262; p,0.001). Thirty
percent (73/242) of HIV infected patients had started ART by the
time of the start of TB treatment; an additional 37 (15%) started
ART within the first three months of TB treatment.
Associations between Baseline Characteristics and ART,
and TB Treatment Adherence
Information on adherence to TB treatment was available for
536 patients. In total, 480 (90%) patients took 90% or more of
expected medication doses of TB treatment; 56 (10%) took ,90%
of expected doses. In univariate analysis age nor sex were
associated with poor adherence (Table 2). There was some
evidence for association of HIV status with poor adherence (OR
1.7; 95%CI 0.97–3.0). A combined variable of HIV status and
antiretroviral treatment was significantly associated with adher-
ence: those who were HIV infected but not on ART were
significantly more often poorly adherent (OR 2.4; 95% CI 1.1–
3.7). In multivariable analysis using logistic regression, adjusting
for age and sex, only untreated HIV was significantly associated
with poor adherence (OR 2.4, 95%CI 1.2–4.6). Addition of any of
the other variables did not change the independent effect of
untreated HIV (data not shown). As this association might have
been artificially created by those who died during the TB
treatment having been more often recorded as non-adherent, we
repeated the analysis restricted to patients who did not die. In that
analysis, based on 463 patients, the independent effect of untreated
HIV status on adherence was even stronger (OR 2.8, 95%CI 1.3–
5.9).
Associations between Baseline Characteristics and
Sputum Smear Conversion among PTB+ Patients
Out of 311 initially PTB+ patients, 292 were still on treatment
two months after start of treatment. A control smear result
(irrespective of timing) was available for 278 (95.2%) of these
patients, at a median (IQR) of 57 days (54–61) after start of





after 2 months Univariate analysis Multivariable analysis
{
OR 95% CI P OR 95% CI P
HIV+, not on co-trimoxazole 38 11 (29.0) 2.18 0.96–4.96
HIV+, on co-trimoxazole 21 8 (38.1) 3.30 1.24–8.78
Unknown HIV status 2
{Multivariate analysis was based on n = 218.
*Farming, housewives, unemployed, labourer, vendor.
#On ART/Co-trimoxazole: already on these treatments at the time of start of TB treatment. Not ART/Co-trimoxazole: started with these treatments after start of TB
treatment or did not start at all before end of treatment.
OR - Odds Ratios; CI - Confidence Interval, PTB Pulmonary TB, ART aniretroviral treatment.
doi:10.1371/journal.pone.0073501.t003
TB Treatment Adherence in Rwanda
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e73501
Table 4. Associations of mortality during TB treatment with demographic and clinical characteristics in 574 TB patients, Rwanda,
2007.
Univariate analysis Multivariable analysis
Baseline characteristics N n (%) who died OR 95% CI P aOR 95% CI P
Sex
Male 353 38 (10.8%) 1 0.25 1 0.82
Female 221 31 (14.0%) 1.35 0.81–2.25 1.07 0.59–1.96
Age (years)
15–24 144 7 (4.9%) 1 ,0.0001 1 0.0002
25–34 196 16 (8.2%) 1.74 0.70–4.35 1.06 0.40–2.84
35–44 125 17 (13.6%) 3.08 1.23–7.70 1.60 0.58–4.44
$45 109 29 (36.6%) 7.09 2.97–16.94 4.72 1.88–11.87
Occupation
Low-income group* 191 19 (10.0%) 1 0.024
Students 43 0 (0.0%) – –
Prisoners 23 3 (13.0%) 1.36 0.37–5.00
Employed 104 8 (7.7%) 0.75 0.32–1.79
Not recorded 213 39 (18.3%) 2.03 1.13–3.65
Type of TB
PTB smear scanty or 1+ 108 2 (1.9%) 1 ,0.0001 1 ,0.0001
PTB smear 2+ 108 4 (3.7%) 2.04 0.37–11.37 1.54 0.25–9.53
PTB smear 3+ 91 7 (7.7%) 4.42 0.89–21.82 3.95 0.78–19.97
PTB smear neg. 63 11 (17.5%) 11.21 2.40–52.44 7.50 1.53–36.70
PTB ‘‘microscopy not-done’’ 33 2 (6.1%) 3.42 0.46–25.28 1.26 0.11–14.87
Extra-pulmonary TB 163 39 (23.9%) 16.67 3.93–70.67 11.49 2.63–50.25
Not recorded 8 4 (50.0%)
HIV status
Negative 323 23 (7.1%) 1 0.0002 1 0.043
Positive 240 41 (17.1%) 2.69 1.56–4.62 1.88 1.01–3.51
Not tested 11 5 (45.5%)
Weight (kg)
#48 204 28 (13.7%) 1 0.45
49–55 176 19 (10.8%) 0.76 0.41–1.42
$56 175 17 (9.7%) 0.68 0.36–1.28
Not recorded 19 5 (26.3%)
Location of health facility
Rural 68 5 (7.4%) 1 0.18
Urban 506 64 (12.7%) 1.82 0.71–4.71
District
Burera 13 3 (23.8%) 1 0.022
Gakenke 24 2 (8.3%) 0.30 0.04–2.11
Gasabo 141 11 (7.8%) 0.28 0.07–1.18
Gicumbi 26 1 (3.9%) 0.13 0.01–1.44
Kicukiro 101 7 (6.9%) 0.25 0.06–1.11
Musanze 57 13 (22.8%) 0.98 0.24–4.12
Ngororero 17 2 (11.8%) 0.44 0.06–3.16
Nyarugenge 195 30 (15.4%) 0.61 0.16–2.33
Antiretroviral treatment1
Not HIV infected 323 23 (7.1%) 1 0.0007
HIV infected, on ART 72 15 (20.8%) 3.43 1.69–6.98
HIV infected, not on ART 168 26 (15.5%) 2.39 1.32–4.33
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predictor of smear conversion (OR for non-conversion for each
additional day since start of TB treatment: 0.94 (95%CI 0.89–
0.99). For 220 (79%) a C2 smear was done between 7 and 9 weeks
after start of TB treatment, and 175 (80%) of these had achieved
sputum smear conversion. In univariate analysis, those with a
smear grade of 3+ at baseline (OR 2.4, 95%CI 1.02–5.7) and those
with HIV infection (OR 2.5, 95%CI 1.3–5.1) were more likely to
remain sputum smear-positive than patients with smear grades 1+
or 2+ at baseline and those not HIV infected, respectively
(Table 3). In a multivariable logistic regression analysis adjusting
for age and sex, independent predictors for non-conversion at 2
months were baseline sputum smear grade (OR = 2.7, 95% CI
1.1–6.6 for comparing those with smear 3+ against those with
smear 1+), and HIV infection (OR = 3.0, 95%CI 1.3–6.7). A
logistic model that included ART/HIV status combined rather
than HIV status was not significantly better (likelihood ratio test,
p = 0.22). Addition of any of the other variables did not change the
independent effect of HIV (data not shown).
We re-examined this association in a model in which we
included patients with a C2 done before 7 weeks after start of TB
treatment whose C2 was already negative, and also patients with a
C2 done more than 9 weeks after start of TB treatment whose C2
was still positive. In this analysis, based on 228 patients, HIV was
still an independent predictor of smear conversion (OR 2.8,
95%CI 1.3–6.2).
Associations between Baseline Characteristics and
Mortality
TB treatment outcome was registered for 574 patients: 236
(41%) were cured, 221 (39%) had completed treatment, 15 (3%)
had treatment failure, 69 (12%) had died, 13 (2%) had defaulted
and 20 (3%) had been transferred out. Of the 69 deaths, 41
occurred among HIV-infected patients. The following factors were
associated with mortality in univariate analysis: age, occupation,
type of TB, HIV status, district, antiretroviral treatment, and co-
trimoxazole prophylaxis (Table 4). In a multivariable analysis only
age (OR = 4.7, 95% CI 1.9–11.9, for age$45 years compared to
age 15–24), HIV infection (OR = 1.9, 95% CI 1.01–3.5, compared
to HIV-negative patients), and type of TB were significantly
associated with death (Table 4). Patients with smear-negative PTB
(OR 7.5, 95%CI 1.5–36.7) and those with EPTB (OR 11.5,
95%CI 2.6–50.3) were significantly more likely to have died,
compared to the patients with scanty or 1+ positive PTB.
Stratified analysis by HIV status showed that among HIV-
negative patients, the highest risk of death was among smear-
negative PTB patients and those with EPTB. Among those co-
infected with HIV, those with 3+ smear-positive PTB and those
with EPTB had the highest risk of death. The interaction between
HIV status and type of TB was statistically significant (p = 0.028,
likelihood ratio test).
Most deaths occurred soon after the start of TB treatment: 39
(57%) had died 1 month after start of TB treatment, 54 (78%) had
died by 2 months, and 63 (91%) by 3 months. Among HIV
infected patients these percentages were very similar: 49%; 71%,
and 90%. We did not observe important differences in timing of
death between those who were treated with ART and those who
were not.
Associations between Baseline Characteristics,
Adherence and Mortality
Next, we examined the effect of treatment adherence on
mortality. Of 535 patients data on treatment outcome and
adherence was available; 68 of them had died (13%). Those who
were non-adherent were significantly more likely to die than those
who were adherent (23% vs. 11%; p = 0.013). The logistic
regression model was based on 517 patients with complete data.
The ORs for age, type of TB and HIV status were not
substantially different from the ORs in the model without
adherence (although HIV status was no longer significant,
OR = 1.8, 95%CI 0.9–3.3, p = 0.08); the independent effect of
poor adherence was strong and very significant (OR = 3.4, 95%CI
1.4–7.8; p = 0.007).
Discussion
In this study among TB patients in Rwanda 10% of the patients
were found to be poorly adherent, defined as having missed
treatment doses on .10% of the days during the treatment period.
The only independent predictor of poor adherence was untreated
HIV co-infection. Twenty percent of PTB+ patients failed to
convert to negative smear status after 2 months of treatment.
Baseline sputum smear grade and HIV infection, whether treated
or not, were independent predictors for non-conversion of sputum
smear at 2 months. Besides older age, type of TB (notably PTB 3+,
PTB2 & EPTB), and HIV infection, non-adherence was an
important determinant of mortality.
According to Rwanda guidelines [13] ART was indicated in
HIV patients with TB, but the timing of start of ART depended on
the form of TB and the CD4 count (if EPTB or CD4 count ,50
cells/mm3 ART should be started 15 days after start TB
Table 4. Cont.
Univariate analysis Multivariable analysis
Baseline characteristics N n (%) who died OR 95% CI P aOR 95% CI P
HIV status unknown 11 5 (45.5%
Co-trimoxazole prophylaxis1
Not HIV infected 323 23 (7.1%) 1 0.0004
HIV+, on co-trimoxazole 107 14 (13.1%) 1.96 0.97–3.97
HIV+ not on co-trimoxazole 133 27 (20.3%) 3.32 1.83–6.05
HIV status unknown 11 5 (45.5%)
*Farming, housewives, unemployed, laborer, vendor.
ART antiretroviral therapy, OR Odds Ratio, aOR ajusted Odds Ratio, CI Confidence Interval. PTB Pulmonary Tuberculosis.
1On ART/co-trimoxazole: on this treatment before start of TB treatment; not on ART/co-trimoxazole: started with this treatment after starting TB treatment or not at all.
doi:10.1371/journal.pone.0073501.t004
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treatment; if CD4 count 50–200 cells/mm3 start after 2 months,
and if CD4 count .200 cells/mm3 the CD4 count should be
repeated after 2 months), and also on the assessment of the health
care worker that the patient was likely to be adherent to ART. In
this study, HIV infected patients that did not start ART before TB
diagnosis were significantly more often non-adherent. The
interpretation of this finding is not straightforward. Possibly these
patients were not started on ART because they were reluctant to
start ART, or possibly ART was delayed until after completion of
TB treatment. Unfortunately we do not have CD4 data or data on
treatment decisions to help interpretation.
A higher smear grade at baseline has also been identified in
other studies as a predictor for non-conversion after 2 months of
treatment [4,16–20]. These patients have a higher bacterial load,
so it may be expected that they need longer treatment until
conversion occurs. The finding that HIV infection is an
independent predictor for non-conversion at 2 months contrasts
with results of earlier studies [16,17,21]. It is unlikely our results
are due to high TB drug resistance levels which are not very high
in Rwanda (3.9% and 9.4% for new and retreated cases
respectively) [22], and HIV was found not to be associated with
multidrug resistance in a systematic review of African studies [23].
HIV infection was independently associated with mortality (in
the model without adherence), an expected finding. A perhaps
surprising finding was that HIV patients who were treated with
ART did not have a lower mortality than those who were not.
This finding is hard to interpret without further clinical data or
CD4 counts. Probably, those on ART were patients with more
advanced HIV disease. Also, ART is not expected to have a strong
impact on mortality until several months after start of ART; time
on ART may have been too short for most to note an effect. With
the increasing accessibility of ART in Rwanda [24,25] the
prognosis of HIV infected TB patients is now being much
improved. Integration of HIV and TB services, as currently being
implemented in Rwanda, will facilitate more timely ART in HIV
patients, including TB patients.
Not surprisingly, older TB patients had a higher risk of death
[3,26,27]. Older people have a higher mortality rate anyway;
underlying disease as a cofactor for TB is more common in older
people and may explain the increased risk of death. EPTB patients
tend to have higher mortality rates than PTB+ patients [28]. The
observation that smear-negative PTB patients had a high risk of
death may suggest that some of these patients were misdiagnosed
[29,30] and in fact suffered from other serious cardiac or
pulmonary conditions rather than TB. As expected, poor
adherence was strongly and independently associated with
mortality.
Limitations
This study has some limitations. First, at the time of our study
sputum smear staining in Rwanda was done by the Kinyoun cold-
staining technique, which is less sensitive than the conventional
Ziehl-Neelsen technique [31,32] (introduced in Rwanda in 2009),
so our data may not be comparable to those of other studies. The
lower sensitivity will also have reduced the sensitivity for sputum
conversion at C2 and cure (reducing the power of the study), and
may have led to misclassification of smear-positive patients as
smear-negative at baseline. Second, the treatment card could not
be retrieved for 144 of 725 patients (20%), who tended to have
more often EPTB, and had more often died. EPTB cases are
normally diagnosed at district hospitals without bacteriological or
histological confirmation [14] due to the complex clinical nature of
their presentation. Most of these patients were subsequently
transferred-out to CDTs close to their homes to start or continue
treatment. Possibly the treatment cards for these patients were
misplaced in the specialized departments where these patients
sought additional specialized treatment for other complications
including HIV [8].
The strength of our study is that it was based on routinely
collected data from 110 clinics, reflecting actual health practice
rather than a typical study setting. This approach comes with some
inherent limitations. Important data were missing for some
patients, like HIV status, sputum-smear after 2 months of intensive
treatment, type of TB, or smear grade at baseline. Further, culture,
drug sensitivity testing, CD4 count and HIV plasma viral load
were not available. Some of the patients who were still smear
positive at two months might in fact have been culture-negative,
their positivity being based on non-viable mycobacteria. In a study
by Su et al, this was the case in 44% of the 2 months smear
positive patients [33]. Next, patients transferred-out were excluded
from the adherence analysis; this may have lead to an
overestimation of the proportion of adherent patients. Finally,
the sample size of PTB+ cases with smear control results at 2
months was only 220, limiting the power of the analysis of smear
conversion.
Conclusions
In Rwanda HIV infection is an important independent
predictor of failure of sputum smear conversion among PTB+
patients. Higher age, poor adherence and type of TB (smear 3+,
smear-negative, or EPTB) are significantly associated with
mortality among TB patients, and HIV infection has a near-
significant effect. Improving adherence is gaining even more
importance, now that increasing proportions of TB patients will be
taking both TB treatment and ART. Operational research is
needed to explore innovative approaches that may improve TB
treatment adherence.
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